Jasper Therapeutics Inc
JSPRW0.068USD
+0.028+70.07%
Close （ET）Quotes delayed by 15 min
0.00Market Cap
--P/E TTM
More Details of Jasper Therapeutics Inc Company
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting mast cell driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU). It also has ongoing programs in diseases where targeting diseased hemopoietic stem cells can provide benefits, such as Lower to Intermediate Risk Myelodysplastic Syndrome (LR-MDS), and stem cell transplant conditioning regimens. The Company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. The SCF/c-Kit pathway is a survival signal for mast cells. It is also developing briquilimab as a one-time conditioning therapy for severe combined immunodeficiency (SCID) patients undergoing a second stem cell transplant for which it is conducting a Phase 1/2 clinical trial.
Jasper Therapeutics Inc Info
Ticker SymbolJSPRW
Company nameJasper Therapeutics Inc
IPO dateNov 20, 2019
CEOMr. Ronald A. (Ron) Martell
Number of employees- -
Security typeCompany Warrant
Fiscal year-end- -
Address2200 Bridge Pkwy Suite #102
CityREDWOOD CITY
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code94065
Phone16505491400
Websitehttps://jaspertx.com/
Ticker SymbolJSPRW
IPO dateNov 20, 2019
CEOMr. Ronald A. (Ron) Martell
Company Executives of Jasper Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Thomas G. (Tom) Wiggans
Mr. Thomas G. (Tom) Wiggans
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Judith Shizuru, M.D., Ph.D.
Dr. Judith Shizuru, M.D., Ph.D.
Director
Director
--
--
Mr. Ronald A. (Ron) Martell
Mr. Ronald A. (Ron) Martell
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Svetlana Lucas, Ph.D.
Dr. Svetlana Lucas, Ph.D.
Independent Director
Independent Director
--
--
Mr. Jeetinder Singh (Jeet) Mahal
Mr. Jeetinder Singh (Jeet) Mahal
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Scott C. Brun, M.D.
Dr. Scott C. Brun, M.D.
Independent Director
Independent Director
--
--
Mr. Herb Cross
Mr. Herb Cross
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
--
--
Mr. Vishal Kapoor
Mr. Vishal Kapoor
Independent Director
Independent Director
--
--
Mr. Christian W. Nolet
Mr. Christian W. Nolet
Independent Director
Independent Director
--
--
Mr. Kurt von Emster
Mr. Kurt von Emster
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Thomas G. (Tom) Wiggans
Mr. Thomas G. (Tom) Wiggans
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Judith Shizuru, M.D., Ph.D.
Dr. Judith Shizuru, M.D., Ph.D.
Director
Director
--
--
Mr. Ronald A. (Ron) Martell
Mr. Ronald A. (Ron) Martell
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Svetlana Lucas, Ph.D.
Dr. Svetlana Lucas, Ph.D.
Independent Director
Independent Director
--
--
Mr. Jeetinder Singh (Jeet) Mahal
Mr. Jeetinder Singh (Jeet) Mahal
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Scott C. Brun, M.D.
Dr. Scott C. Brun, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholder Types
Shareholders
Proportion
Other
100.00%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
12
3.37M
0.00%
-2.00M
2025Q3
10
3.02M
0.00%
-601.83K
2025Q2
13
913.90K
0.00%
-2.83M
2025Q1
14
913.90K
0.00%
-2.83M
2024Q4
18
926.81K
0.00%
-3.24M
2024Q3
18
3.13M
0.00%
-996.42K
2024Q2
18
3.10M
0.00%
-894.34K
2024Q1
18
2.96M
0.00%
-947.54K
2023Q4
18
2.96M
0.00%
+24.06K
2023Q3
18
2.40M
0.00%
-471.12K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Boothbay Fund Management, LLC
357.45K
0%
+357.45K
--
Sep 30, 2025
Clear Street Group Inc
120.00
0%
+120.00
--
Sep 30, 2025
BofA Global Research (US)
101.00
0%
+101.00
--
Sep 30, 2025
Walleye Capital LLC
560.06K
0%
--
--
Sep 30, 2025
Tenor Capital Management Co., L.P.
250.00K
0%
--
--
Sep 30, 2025
Zazove Associates, LLC
--
0%
-65.46K
-100.00%
Sep 30, 2025
Walleye Trading, LLC
34.14K
0%
--
--
Sep 30, 2025
UBS Financial Services, Inc.
--
0%
-1.30K
-100.00%
Jun 30, 2025
TD Securities (USA) LLC
--
0%
-2.21M
-100.00%
Dec 31, 2024
Independent Financial Partners
50.00
0%
--
--
Sep 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Jasper Therapeutics Inc?
The top five shareholders of Jasper Therapeutics Inc are:
Boothbay Fund Management, LLC holds 357.45K shares, accounting for 0.00% of the total shares.
Clear Street Group Inc holds 120.00 shares, accounting for 0.00% of the total shares.
BofA Global Research (US) holds 101.00 shares, accounting for 0.00% of the total shares.
Walleye Capital LLC holds 560.06K shares, accounting for 0.00% of the total shares.
Tenor Capital Management Co., L.P. holds 250.00K shares, accounting for 0.00% of the total shares.
Boothbay Fund Management, LLC holds 357.45K shares, accounting for 0.00% of the total shares.
Clear Street Group Inc holds 120.00 shares, accounting for 0.00% of the total shares.
BofA Global Research (US) holds 101.00 shares, accounting for 0.00% of the total shares.
Walleye Capital LLC holds 560.06K shares, accounting for 0.00% of the total shares.
Tenor Capital Management Co., L.P. holds 250.00K shares, accounting for 0.00% of the total shares.
What are the top three shareholder types of Jasper Therapeutics Inc?
The top three shareholder types of Jasper Therapeutics Inc are:
Other
Other
How many institutions hold shares of Jasper Therapeutics Inc (JSPRW)?
As of 2025Q4, 12 institutions hold shares of Jasper Therapeutics Inc, with a combined market value of approximately 3.37M, accounting for --% of the total shares. Compared to 2025Q3, institutional shareholding has increased by --.
What is the biggest source of revenue for Jasper Therapeutics Inc?
In --, the -- business generated the highest revenue for Jasper Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
